REFERENCES
1. Chan NSL, Cross C, Bowen J, et al. The gut-heart axis in cardio-oncology. Cardiovasc Res. 2026;122:1573-88.
2. Lyon AR, López-Fernández T, Couch LS, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229-361.
3. Bhutani V, Varzideh F, Wilson S, Kansakar U, Jankauskas SS, Santulli G. Doxorubicin-induced cardiotoxicity: a comprehensive update. J Cardiovasc Dev Dis. 2025;12:207.
4. Narasimhulu CA, Imaralu O, Khan M, Singla DK. Interplay of oxidative stress and inflammatory mechanisms in doxorubicin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2026;331:H619-36.
5. Barragan-Carrillo R, Zengin ZB, Pal SK. Microbiome Modulation for the Treatment of Solid Neoplasms. J Clin Oncol. 2025;43:2734-8.
6. Gao YQ, Tan YJ, Fang JY. Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention. Nat Rev Clin Oncol. 2025;22:499-516.
7. Hajjar R, Mars RAT, Kashyap PC. Harnessing the microbiome for cancer therapy. Nat Rev Microbiol. 2026;24:392-407.
8. Huang J, Hou X, Zhou N, et al. Novel Protective role for gut microbiota-derived metabolite PAGln in doxorubicin-induced cardiotoxicity. Cardiovasc Drugs Ther. 2026;40:65-80.
9. Hou J, Ren J, Abbas S, et al. Targeting the gut-heart axis: dextran from gut-derived Weissella cibaria alleviates doxorubicin-induced cardiotoxicity by attenuating low-grade endotoxemia. J Agric Food Chem. 2025;73:33084-98.
10. Tonon CR, Pereira AG, Ferreira NF, et al. The gut-heart axis and its role in doxorubicin-induced cardiotoxicity: a narrative review. Microorganisms. 2025;13:855.
11. Cao H, Dai H, Li S, et al. Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells. Sci Rep. 2025;15:20547.
12. Huang J, Wei S, Jiang C, et al. Involvement of abnormal gut microbiota composition and function in doxorubicin-induced cardiotoxicity. Front Cell Infect Microbiol. 2022;12:808837.
13. An L, Wuri J, Zheng Z, Li W, Yan T. Microbiota modulate doxorubicin induced cardiotoxicity. Eur J Pharm Sci. 2021;166:105977.
14. Yin J, You Y, Mao J, Qi J, Zhang X, Hong Y. NLRP3 inflammasome regulates doxorubicin-induced cardiotoxicity by modulating the abundance of gut microbiota. Toxicol Appl Pharmacol. 2025;502:117455.
15. Reyes F, Buehning F, Lerchner T, et al. Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum. Br J Pharmacol 2026.
16. Jo W, Sun V, Čiháková D. Immune mechanisms of viral, autoimmune, and immune checkpoint inhibitor-associated myocarditis. Immunol Rev. 2026;338:e70111.
17. Huang J, Xu X, Jin Y, et al. Mechanisms and biomarkers of immune checkpoint inhibitor-associated myocarditis: from T cell imbalance to multicellular crosstalk. Front Immunol. 2026;17:1752354.
18. Chen Z, Li G, Tang X, Liu X. Cardiovascular adverse events associated with Immune checkpoint inhibitors from the perspective of gut microecology: potential roles and research advances of the gut microbiota. J Cardiovasc Pharmacol. 2026;88:104-14.
19. Huang Z, Mei X, Zhou Y. The gut microbiota: an emerging therapeutic target for ICI-associated myocarditis. Front Cell Infect Microbiol. 2026;16:1752485.
20. Verheijden RJ, van Eijs MJM, Paganelli FL, et al.; UNICIT-consortium. Gut microbiome and immune checkpoint inhibitor toxicity. Eur J Cancer. 2025;216:115221.
21. Gong J, Neilan TG, Zlotoff DA. Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: insights from mouse and human. Immunol Rev. 2023;318:70-80.
22. Hu S, Luo C, Wan S, et al. Modulating the gut microbiome to enhance cancer immunotherapy: a systematic review and meta-analysis of probiotics and FMT as adjuncts. BMC Cancer. 2026;26.
23. Wang S, Fan X, Zhang C, et al. Oral bioinspired peroxisome-engineered probiotics for modulating gut microbiota homeostasis and alleviating cardiac chemotherapy toxicity. Adv Sci (Weinh). 2026;13:e19344.
24. DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381:2043-50.




